Rohto Pharmaceutical Co (4527) AI Stock Analysis

• Market Cap: ¥594.44B
• Dividend Yield: 1.6%
• Average Volume (3M): 606.37K
• Price to Earnings (P/E): 16.2
• Beta (1Y): 0.51
• Revenue Growth: 18.35%
• EPS Growth: 31.87%
• Country: JP
• Employees: 7,259
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 26.03
• Shares Outstanding: 236,178,310
• 10 Day Avg. Volume: 537,400
• 30 Day Avg. Volume: 606,370
• PEG Ratio: 43.69
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 1.65
• P/FCF Ratio: 18.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,790.00
• Price Target Upside: 8.98% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: ¥2,684.00 ▲(4.84% Upside)

Rohto Pharmaceutical's overall stock score is driven by its strong financial performance, which is the most significant factor. The technical analysis indicates a lack of strong momentum, which slightly offsets the financial strengths. The valuation is reasonable, providing a balanced outlook.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective product strategy, supporting long-term business expansion.

Balance Sheet Health

A strong balance sheet with low leverage enhances financial flexibility, allowing for strategic investments and resilience against downturns.

Cash Flow Management

Effective cash flow management ensures the company can fund operations, invest in growth opportunities, and return value to shareholders.

Negative Factors

EBIT Margin Decline

A decline in EBIT margin could signal rising costs or pricing pressures, potentially impacting future profitability if not addressed.

Technical Analysis Weakness

While primarily a short-term indicator, persistent technical weakness could reflect underlying market concerns affecting investor sentiment.

Lack of Strong Momentum

Lack of momentum may hinder stock performance, affecting capital raising ability and investor confidence over the medium term.

Rohto Pharmaceutical Co Business Overview & Revenue Model

Company Description

Rohto Pharmaceutical Co., Ltd. is a prominent Japanese pharmaceutical and consumer healthcare company, known for its innovative products in the fields of ocular health, dermatology, and over-the-counter (OTC) pharmaceuticals. Founded in 1899, Rohto operates in multiple sectors, including pharmaceuticals, healthcare, and cosmetics, focusing on the development and distribution of a wide range of products such as eye drops, skincare products, and dietary supplements. The company is recognized for its commitment to research and development, continually introducing new products to meet consumer needs across various markets.

How the Company Makes Money

Rohto Pharmaceutical generates revenue primarily through the sale of its consumer healthcare products, which include eye care solutions, skin care products, and OTC medications. The company has a diverse portfolio, with its eye drops being among its best-selling items. In addition to its domestic sales in Japan, Rohto has expanded its market presence internationally, particularly in Asia and North America, contributing significantly to its revenue growth. Key revenue streams include direct sales to consumers, partnerships with retailers, and distribution agreements with other pharmaceutical firms. The company also benefits from strategic collaborations and joint ventures, enhancing its market reach and product offerings, which play a crucial role in driving its earnings.

Rohto Pharmaceutical Co Financial Statement Overview

Summary

Rohto Pharmaceutical exhibits strong financial health with consistent revenue growth, strong profit margins, a robust balance sheet with low leverage, and effective cash flow management. These factors indicate a well-managed company with a strong market position.

Income Statement

Rohto Pharmaceutical has shown a consistent upward trend in revenue growth, with a notable increase of 13.94% in the latest year. Gross profit margin remains strong at 54.88%, and the net profit margin is stable at 10.05%. Despite a slight dip in EBIT margin to 12.46%, the company maintains healthy profitability metrics overall.

Balance Sheet

The company's balance sheet is robust, highlighted by a low debt-to-equity ratio of 0.19, indicating low leverage and financial stability. The equity ratio is healthy at 61.64%, suggesting a strong capital structure. Return on equity stands at 11.92%, showcasing efficient use of equity to generate profit.

Cash Flow

Rohto Pharmaceutical has demonstrated solid cash flow management with a free cash flow growth rate of 9.90%. The operating cash flow to net income ratio is healthy at 1.19, indicating strong cash generation relative to net income. The free cash flow to net income ratio is also favorable at 0.90.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	322.23B	308.63B	270.84B	238.66B	199.65B	181.05B
Gross Profit	181.03B	169.38B	157.29B	137.42B	116.49B	106.73B
EBITDA	52.16B	56.42B	50.40B	42.34B	35.81B	28.61B
Net Income	34.29B	31.00B	30.94B	26.38B	21.13B	16.74B
Balance Sheet
Total Assets	428.33B	421.88B	346.18B	309.68B	274.63B	225.79B
Cash, Cash Equivalents and Short-Term Investments	75.84B	77.16B	89.21B	79.95B	72.79B	52.96B
Total Debt	48.88B	50.22B	10.49B	11.69B	21.38B	8.10B
Total Liabilities	144.18B	150.43B	99.14B	94.60B	90.80B	69.18B
Stockholders Equity	266.74B	260.10B	246.32B	209.57B	178.28B	155.91B
Cash Flow
Free Cash Flow	0.00	27.84B	25.33B	21.02B	15.92B	9.70B
Operating Cash Flow	0.00	36.92B	34.24B	30.92B	27.25B	20.01B
Investing Cash Flow	0.00	-89.17B	-16.32B	-13.18B	-16.41B	-10.24B
Financing Cash Flow	0.00	35.32B	-13.78B	-16.20B	3.47B	-2.35B

Rohto Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2560.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4527, the sentiment is Positive. The current price of 2560 is above the 20-day moving average (MA) of 2504.67, above the 50-day MA of 2461.47, and above the 200-day MA of 2296.38, indicating a bullish trend. The MACD of 24.94 indicates Negative momentum. The RSI at 61.11 is Neutral, neither overbought nor oversold. The STOCH value of 85.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4527.

Rohto Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4912	76 Outperform	¥462.20B	16.05	9.77%	1.75%	2.18%	60.81%
4527	71 Outperform	¥594.44B	16.25	13.22%	1.60%	18.35%	31.87%
4927	68 Neutral	¥292.91B	29.33	6.05%	3.93%	-1.16%	36.30%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
4967	57 Neutral	¥389.73B	33.88	5.37%	1.96%	-3.33%	13.76%
4922	57 Neutral	¥302.71B	40.46	2.72%	2.61%	1.37%	-5.60%
4911	49 Neutral	¥931.41B	-16.97	―	2.12%	-1.20%	-2896.72%

Rohto Pharmaceutical Co Corporate Events

Rohto Pharmaceutical Acquires OBAGI Trademarks in Japan

Rohto Pharmaceutical Co., Ltd. has announced the acquisition of OBAGI-related trademarks in Japan from OBAGI COSMECEUTICALS LLC, a subsidiary of Waldencast plc, for USD 82.5 million. This strategic move allows Rohto to permanently secure licensing and sales rights for OBAGI products in Japan, aiming to strengthen its domestic market position and expand into new channels such as medical clinics.

Rohto Pharmaceutical Revises Earnings and Dividend Forecasts Upward

Rohto Pharmaceutical Co., Ltd. has revised its earnings and dividend forecasts for the fiscal year ending March 31, 2026, due to stronger-than-expected performance in Japan, Asia, and the Americas. The company anticipates higher net sales and profits, leading to an increased year-end dividend of 22 yen per share, up from the previous forecast, reflecting the company’s commitment to returning profits to shareholders.

Rohto Pharmaceutical Reports Strong Financial Growth and Strategic Expansion

Rohto Pharmaceutical Co. reported a significant increase in its financial performance for the six months ended September 30, 2025, with net sales rising by 18.1% and profit attributable to owners of the parent increasing by 36.6% compared to the previous year. The company also announced a revision in its dividend forecast and highlighted the inclusion of Rohto MediLuxe Europe S.A.S.U. in its consolidation scope, indicating strategic expansion and a positive outlook for stakeholders.